Key facts
- It has raised $11.9M across 3 recorded rounds; the latest was Early Stage VC ($8.4M) in Aug 2025.
- Notable investors include I3P.
- Continuity Biosciences has filed 3 Form Ds with the SEC since 2024, most recently Aug 2025 ($8.4M sold to 13 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 3 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Continuity Biosciences
Funding rounds
3 roundsAbout Continuity Biosciences
Developer of advanced drug delivery technologies designed for treating complex diseases. The company develops technologies for cell reprogramming and drug delivery to create combination products that enhance novel therapies using technology portfolios ranging from nanofluidic systems for drug delivery to cell storage systems that enable donor/stem cell transplantation and immune modulation, enabling medical institutions to treat chronic and complex diseases.
- Sector
- Healthcare
- HQ
- Bradenton, FL, United States
- Founded
- 2024
- Employees
- 10
- Website
- continuitybiosciences.com/
- Ownership
- Privately Held (backing)
Continuity Biosciences doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Continuity Biosciences shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Continuity Biosciences in its N-PORT filings yet. We sweep new filings monthly.